Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
Volume
200.00
Value Traded
0.00
Short % Float
-
Days to Cover
15.4
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
-
EPS (TTM)
-
P/E Ratio
-
Ent. Value
-
Total Shares
-
Float Shares
-
Insiders
-
Institutions
-
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
IOBTQ Catalyst Timeline
Dated clinical, regulatory and corporate events for IO Biotech, Inc.
Past FDA Catalysts and PDUFA Decisions
How IOBTQ actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
2
Drugs Scored
rNPV / MCap
Top Drug
Top 44%
Micro Cap(rank 303 of 687)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| IO102-IO103 VaccinesNCT05155254 | Metastatic Melanoma | Phase 3 | ACTIVE NOT_RECRUITING | 407 | Sep 1, 2027 | ||||||
| IO102-IO103 VaccinesNCT05280314 | Melanoma | Phase 2 | RECRUITING | 60 | Jan 1, 2027 | ||||||
| IO102-IO103 VaccinesCompletedNCT05077709 | Lung Cancer Non Small Cell | Phase 2 | COMPLETED | 63 | Feb 8, 2026 | ||||||
| IO102 VaccinesCompletedNCT03562871 | NSCLC | Phase 1/2 | COMPLETED | 109 | Apr 12, 2022 |
Clinical Trial Results
Readouts, endpoints and source filings for every IOBTQ program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| No insider trades match the selected filters. | |||||
Hedge Fund 13F Activity
Hedge Funds invested in IOBTQ
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in IOBTQ for Q2 2026. | ||||
Ownership Trends
IOBTQ Short Interest
Shares sold short, counted twice a month.
-
Short % of Float
of tradable shares sold short
470.3K
Shares Sold Short
-0.1% vs prior count
15.4 Very high
Days to Cover
trading days of normal volume to buy every short share back
30.6K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How IOBTQ ranks across every disease it competes in
Competitive Position is a premium feature
See how IOBTQ ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialIOBTQ News
About IO Biotech, Inc.
BIOPHARMAWATCH ELITE
Trade the next IOBTQ catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime